Coherus Oncology (CHRS) EBITDA Margin (2013 - 2026)
Coherus Oncology's EBITDA Margin came in at -219.96% for Q2 2026, up 213.73 percentage points from -433.68% a year earlier and up 66.56 percentage points from the prior quarter.
Powered by 
Analysis
Coherus Oncology (CHRS) EBITDA Margin (2013 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Coherus Oncology reported EBITDA Margin of -304.48%, up 259.77 percentage points year-over-year; for FY2025, it was -420.21%, up 316.38 percentage points from FY2024.
- EBITDA Margin carries a five-year change of -453.67 percentage points (FY2020 to FY2025).
- Going back by year, EBITDA Margin was -736.58% in FY2024 (-659.07 pp), -77.52% in FY2023 (+42.45 pp), -119.97% in FY2022 (-40.22 pp) and -79.74% in FY2021 (-113.20 pp).
- The Q2 2026 figure represents the highest quarterly EBITDA Margin since Q4 2023.
- Year-over-year, EBITDA Margin has increased for four consecutive quarters, with an average year-over-year change of +265.85 percentage points over the last eight quarters.
- The fastest year-over-year change in EBITDA Margin over five years came in Q1 2025 (a gain of 2287.61 percentage points), and the weakest in Q1 2024 (a drop of 2665.82 percentage points).
- Business Quant data shows CHRS's EBITDA Margin at -286.52% (Q1 2026), -352.87% (Q4 2025) and -374.79% (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,122.91 Bn | 1,091.50 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 615.09 Bn | 533.62 Bn | 17.26 Bn | 35.95% |
| 3 | AbbVie | 504.75 Bn | 477.86 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 360.18 Bn | 314.55 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 292.05 Bn | 256.04 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 256.09 Bn | 229.78 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 233.63 Bn | 189.02 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 194.49 Bn | 168.69 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 168.35 Bn | 114.99 Bn | 10.94 Bn | 39.16% |
| 10 | Coherus Oncology | 155.59 Mn | -480.55 Mn | 10.07 Mn | -219.96% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -219.96% |
| Mar 31, 2026 | -286.52% |
| Dec 31, 2025 | -352.87% |
| Sep 30, 2025 | -374.79% |
| Jun 30, 2025 | -433.68% |
| Mar 31, 2025 | -584.14% |
| Dec 31, 2024 | -573.53% |
| Sep 30, 2024 | -748.63% |
| Jun 30, 2024 | -373.34% |
| Mar 31, 2024 | -2,871.75% |
| Dec 31, 2023 | -73.47% |
| Sep 30, 2023 | -40.93% |
| Jun 30, 2023 | -56.36% |
| Mar 31, 2023 | -203.91% |
| Dec 31, 2022 | -109.46% |
| Sep 30, 2022 | -173.03% |
| Jun 30, 2022 | -70.04% |
| Mar 31, 2022 | -127.19% |
| Dec 31, 2021 | -51.27% |
| Sep 30, 2021 | -37.33% |
API Access
Coherus Oncology EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CHRS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "CHRS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CHRS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();